These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9374513)

  • 41. Synthesis and characterization of more potent analogues of hirudin fragment 1-47 containing non-natural amino acids.
    De Filippis V; Quarzago D; Vindigni A; Di Cera E; Fontana A
    Biochemistry; 1998 Sep; 37(39):13507-15. PubMed ID: 9753436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond.
    DiMaio J; Ni F; Gibbs B; Konishi Y
    FEBS Lett; 1991 Apr; 282(1):47-52. PubMed ID: 2026264
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin.
    Skrzypczak-Jankun E; Carperos VE; Ravichandran KG; Tulinsky A; Westbrook M; Maraganore JM
    J Mol Biol; 1991 Oct; 221(4):1379-93. PubMed ID: 1942057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The molecular environment of the Na+ binding site of thrombin.
    Zhang E; Tulinsky A
    Biophys Chem; 1997 Jan; 63(2-3):185-200. PubMed ID: 9108691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Replacement of thrombin residue G184 with Lys or Arg fails to mimic Na+ binding.
    Roy DB; Rose T; Di Cera E
    Proteins; 2001 May; 43(3):315-8. PubMed ID: 11288181
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of activation peptide bond cleavage and fragment 2 interactions on the pathway of exosite I expression during activation of human prethrombin 1 to thrombin.
    Anderson PJ; Nesset A; Bock PE
    J Biol Chem; 2003 Nov; 278(45):44482-8. PubMed ID: 12939269
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure of thrombin complexed with selective non-electrophilic inhibitors having cyclohexyl moieties at P1.
    Krishnan R; Mochalkin I; Arni R; Tulinsky A
    Acta Crystallogr D Biol Crystallogr; 2000 Mar; 56(Pt 3):294-303. PubMed ID: 10713516
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of thrombin-catalyzed factor V activation by bothrojaracin.
    Arocas V; Lemaire C; Bouton MC; Bezeaud A; Bon C; Guillin MC; Jandrot-Perrus M
    Thromb Haemost; 1998 Jun; 79(6):1157-61. PubMed ID: 9657441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular Interactions of Thrombin.
    Tulinsky A
    Semin Thromb Hemost; 1996; 22(2):117-24. PubMed ID: 8807707
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of prothrombin fragment 1 in the pathway of regulatory exosite I formation during conversion of human prothrombin to thrombin.
    Anderson PJ; Bock PE
    J Biol Chem; 2003 Nov; 278(45):44489-95. PubMed ID: 12939270
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structure-function relationships of the C-terminal functional domain of hirudin and its variants.
    Krstenansky JL; Mao SJ
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):91-6. PubMed ID: 1773003
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase.
    Kretz CA; Stafford AR; Fredenburgh JC; Weitz JI
    J Biol Chem; 2006 Dec; 281(49):37477-85. PubMed ID: 17046833
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How Na+ activates thrombin--a review of the functional and structural data.
    Huntington JA
    Biol Chem; 2008 Aug; 389(8):1025-35. PubMed ID: 18979627
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bothrojaracin: a potent two-site-directed thrombin inhibitor.
    Arocas V; Zingali RB; Guillin MC; Bon C; Jandrot-Perrus M
    Biochemistry; 1996 Jul; 35(28):9083-9. PubMed ID: 8703912
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens.
    Reuning U; Bang NU
    Arterioscler Thromb; 1992 Oct; 12(10):1161-70. PubMed ID: 1327097
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exosite 2-Directed Ligands Attenuate Protein C Activation by the Thrombin-Thrombomodulin Complex.
    Chen K; Stafford AR; Wu C; Yeh CH; Kim PY; Fredenburgh JC; Weitz JI
    Biochemistry; 2017 Jun; 56(24):3119-3128. PubMed ID: 28549218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human alpha-thrombin inhibition by the active site titrant N alpha-(N,N-dimethylcarbamoyl)-alpha-azalysine p-nitrophenyl ester: a comparative kinetic and X-ray crystallographic study.
    Nardini M; Pesce A; Rizzi M; Casale E; Ferraccioli R; Balliano G; Milla P; Ascenzi P; Bolognesi M
    J Mol Biol; 1996 May; 258(5):851-9. PubMed ID: 8637015
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Contribution of lysine 60f to S1' specificity of thrombin.
    Rezaie AR; Olson ST
    Biochemistry; 1997 Feb; 36(5):1026-33. PubMed ID: 9033392
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structural and Functional Characterization of Hirudin P6 Derived Novel Bivalent Thrombin Inhibitors - Studying the Effect of Linker Length and Glycosylation on Their Function.
    Shabareesh P; Kaur KJ
    Chem Biol Drug Des; 2016 Jul; 88(1):129-41. PubMed ID: 26850929
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Release of fibrinopeptides by the slow and fast forms of thrombin.
    Vindigni A; Di Cera E
    Biochemistry; 1996 Apr; 35(14):4417-26. PubMed ID: 8605191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.